SCCF1 Stably Expressing Luciferase Cell Line

Cat. No.
T6446
Unit
1x10⁶ cells / 1 ml
Price
Inquiry

Worried about losing your cells due to contamination issues, thawing or growth difficulties or even a random freezer breakdown?

Enjoy peace of mind knowing that you can be covered under abm’s Cell Line Insurance

Cat. No. T6446
Name SCCF1 Stably Expressing Luciferase Cell Line
Description

Developed from a laryngeal squamous cell carcinoma of a cat. The cells were stably transfected with a plasmid containing a luciferase-YFP fusion construct. SCCF1 cells can be used for experiments on genetic dysregulation in neoplastic keratinocytes of the feline oropharynx. Will form tumors in nude mice, and will have marked invasion of regional bone These cells are a useful in vitro model for head and neck cancer.

Organism Cat (Feline)
Tissue Larynx
Donor History Cat, Laryngeal squamous cell carcinoma
Growth Properties Adherent, epithelial-like
Cell Type Stable Cell Lines
Unit 1x10⁶ cells / 1 ml
Storage Condition Vapor phase of liquid nitrogen, or below -130°C.
Shipping Conditions Ship with dry ice.
Product Format Frozen
Intended Use This product is intended for laboratory research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use.
BioSafety II
Certificate of Analysis For batch-specific test results, refer to the applicable certificate of analysis that can be found at www.abmgood.com.
Growth Conditions Use of PriCoat™ T25 Flasks (G299) or Applied Cell Extracellular Matrix (G422) is required for cell adhesion to the culture vessels. PriGrow III (TM003) + 10% FBS + 1% Penicillin/Streptomycin Solution (G255), 37.0°C, 5% CO₂. Selection with 0.4 mg/ml G418 (G271)
Unpacking and Storage Instructions

1. Visually examine the packaging containers for signs of leakage or breakage.

2. Immediately transfer frozen cells from dry ice packaging to a temperature below -130°C, preferably in liquid nitrogen vapor phase storage, until ready for use.

To ensure the highest level of viability, thaw the vial and initiate culture as soon as possible upon receipt. If continued storage is desired, the vial should only be stored below -130°C or in liquid nitrogen vapor phase. Do not store at -70°C, as it will result in loss of viability.


Thawing Protocol

1. Thaw cells quickly in a 37°C water bath while agitating gently (maximum 2 minutes). The vial cap should be kept above the water level to minimize the risk of contamination.

2. Decontaminate the vial by spraying and wiping the exterior of the vial with 70% ethanol. From this point onwards, all operations should be strictly carried out inside a biological safety cabinet using aseptic conditions.

3. Transfer the cell suspension into a 15ml sterile conical tube containing 5ml of pre-warmed, complete growth media. Centrifuge cells at 125xg for 5-7 minutes.

4. Aspirate the supernatant without disturbing the cell pellet. Re-suspend the cell pellet in the recommended pre-warmed, complete growth media and dispense into a T25 culture flask.

5. Incubate the cells at the recommended conditions.

Subculture Protocol

Volumes given below are for a T75 flask; proportionally increase or decrease the volume as required per culture vessel size. Subculture cells once the culture vessel is 80% confluent.

1. Aspirate the culture media, and add 2-3ml of pre-warmed 0.25% Trypsin-EDTA to the culture vessel.

2. Observe the cells under a microscope to confirm detachment (typically within 2-10 minutes). Cells that are difficult to detach can be put in 37°C, for several minutes to facilitate detachment.

3. Neutralize Trypsin-EDTA by adding an equal volume of the complete growth media into the culture vessel.

4. Transfer the culture suspension into a sterile centrifuge tube, and centrifuge at 125xg for 5 minutes. The actual centrifuge duration and speed may vary depending on the cell type.

5. Aspirate the supernatant, and re-suspend the pellet with pre-warmed fresh complete growth media. Add appropriate aliquots of the cell suspension to new culture vessels, as desired.

6. Incubate the cells at the recommended conditions.

Cryopreservation Cryopreservation Medium (TM024), or complete growth media with 10% DMSO.
Split Ratio 1:5
Expression Luciferase, YFP
Material Citation If use of this material results in a scientific publication, please cite the material in the following manner: Applied Biological Materials Inc, Cat. No. T6446.
Warranty abm warrants that cell lines shall be viable upon initiation of culture for a period of thirty (30) days after shipment and that they shall meet the specifications on the applicable abm Material Product Information sheet, certificate of analysis, and/or catalog description. Such thirty (30) day period is referred to herein as the "Warranty Period”.
Disclaimer

1. Sale of this item is subjected to the completion of a Material Transfer Agreement (MTA) by the purchasing individual/institution for each cell line. If you have any questions regarding this, please contact us at [email protected].

2. All test parameters provided in the CoA are conducted using abm's standardized culture system and The stated values may vary under the end-user's culture conditions. Please verify that the product is suitable for your studies by referencing published papers or ordering RNA (0.5 μg, Cat.# C207, $450.00) or cell lysate (100 μg, Cat.# C206, $600.00) to perform preliminary experiments, or alternatively use our Gene Expression Assay Service (Cat# C138). All sales are final.

3. We recommend live cell shipments for ease of cell transfer and this option can be requested at the time of order placement. Please note that the end-user will need to evaluate the feasibility of live cell shipment by taking into account the final destination's temperature variation and its geographical location.

4. All of abm's cell biology products are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its cell biology product(s) in therapeutic/diagnostic or any other non-RUO application(s).

5. abm makes no warranties or representations as to the accuracy of the information on this site. Citations from literature are provided for informational purposes only. abm does not warrant that such information has been shown to be accurate.

6. abm warrants that cell lines shall be viable upon initiation of culture for a period of thirty (30) days after shipment and that they shall meet the specifications on the applicable abm Material Product Information sheet, certificate of analysis, and/or catalog description. Such thirty (30) day period is referred to herein as the "Warranty Period".

Depositor Ohio State University
Application Research Use Only.
Material Citation If use of this material results in a scientific publication, please cite the material in the following manner: Applied Biological Materials Inc, Cat. No. T6446
Print & Download Datasheet
  • Tannehill-Gregg, S., Kergosien, E. & Rosol, T.J. Feline head and neck squamous cell carcinoma cell line: characterization, production of parathyroid hormone-related protein, and regulation by transforming growth factor-beta. In vitro cellular & developmental biology. Animal 37, 676-683 (2001).


    Tannehill-Gregg, S.H., Levine, A.L. & Rosol, T.J. Feline head and neck squamous cell carcinoma: a natural model for the human disease and development of a mouse model. Vet.Comp Oncol. 4, 84-97 (2006).


    Heller, D.A., Fan, T.M., de Lorimier, L.P., Charney, S.C., Barger, A.M., Tannehill-Gregg, S.H., Rosol, T.J. & Wallig, M.A. In vitro cyclooxygenase-2 protein expression and enzymatic activity in neoplastic cells. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 21, 1048-1055 (2007).


    Wypij, J.M., Fan, T.M., Fredrickson, R.L., Barger, A.M., de Lorimier, L.P. & Charney, S.C. In vivo and in vitro efficacy of zoledronate for treating oral squamous cell carcinoma in cats. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 22, 158-163 (2008).


    Wakshlag, J.J., Peters-Kennedy, J., Bushey, J.J. & Loftus, J.P. 5-lipoxygenase expression and tepoxalin-induced cell death in squamous cell carcinomas in cats. Am J Vet Res 72, 1369-1377 (2011).


    Bergkvist, G.T., Argyle, D.J., Morrison, L., MacIntyre, N., Hayes, A. & Yool, D.A. Expression of epidermal growth factor receptor (EGFR) and Ki67 in feline oral squamous cell carcinomas (FOSCC). Veterinary and comparative oncology 9, 106-117 (2011).


    Bergkvist, G.T., Argyle, D.J., Pang, L.Y., Muirhead, R. & Yool, D.A. Studies on the inhibition of feline EGFR in squamous cell carcinoma: enhancement of radiosensitivity and rescue of resistance to small molecule inhibitors. Cancer biology & therapy 11, 927-937 (2011).


    Pang, L.Y., Bergkvist, G.T., Cervantes-Arias, A., Yool, D.A., Muirhead, R. & Argyle, D.J. Identification of tumour initiating cells in feline head and neck squamous cell carcinoma and evidence for gefitinib induced epithelial to mesenchymal transition. Vet J 193, 46-52 (2012).


    Balkman, C.E., Gieger, T.L., Zgola, M.M., Lewis, L.D. & McEntee, M.C. In Vitro Characterization of Docetaxel as a Radiosensitizer in Canine and Feline Cancer Cell Lines. Open Journal of Veterinary Medicine 2, 285-292 (2012).


    Martin, C.K., Dirksen, W.P., Shu, S.T., Werbeck, J.L., Thudi, N.K., Yamaguchi, M., Wolfe, T.D., Heller, K.N. & Rosol, T.J. Characterization of bone resorption in novel in vitro and in vivo models of oral squamous cell carcinoma. Oral Oncol 48, 491-499 (2012).


    Wypij, J.M. & Pondenis, H. Surrogate biomarkers interleukin-6 and interleukin-10 in a spontaneous feline model of head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 32, abstr e17056 (2014).


    Parviainen, S., Autio, K., Vaha-Koskela, M., Guse, K., Pesonen, S., Rosol, T.J., Zhao, F. & Hemminki, A. Incomplete but infectious vaccinia virions are produced in the absence of oncolysis in feline SCCF1 cells. PloS one 10, e0120496 (2015).


    Brown, M.E., Bear, M.D., Rosol, T.J., Premanandan, C., Kisseberth, W.C. & London, C.A. Characterization of STAT3 expression, signaling and inhibition in feline oral squamous cell carcinoma. BMC Vet Res 11, 206 (2015).


    Supsavhad, W., Dirksen, W.P., Hildreth, B.E. & Rosol, T.J. p16, pRb, and p53 in Feline Oral Squamous Cell Carcinoma. Veterinary sciences 3(2016).


    Supsavhad, W., Dirksen, W.P., Martin, C.K. & Rosol, T.J. Animal models of head and neck squamous cell carcinoma. Vet J 210, 7-16 (2016).


    Cannon, C.M., Trembley, J.H., Kren, B.T., Unger, G.M., O'Sullivan, M.G., Cornax, I., Modiano, J.F. & Ahmed, K. Evaluation of protein kinase CK2 as a therapeutic target for squamous cell carcinoma of cats. Am J Vet Res 78, 946-953 (2017).


    Cannon, C.M., Trembley, J.H., Kren, B.T., Unger, G.M., O'Sullivan, M.G., Cornax, I., Modiano, J.F. & Ahmed, K. Therapeutic Targeting of Protein Kinase CK2 Gene Expression in Feline Oral Squamous Cell Carcinoma: A Naturally Occurring Large-Animal Model of Head and Neck Cancer. Hum Gene Ther Clin Dev 28, 80-86 (2017).


    Trembley, J.H., Kren, B.T., Abedin, M.J., Vogel, R.I., Cannon, C.M., Unger, G.M. & Ahmed, K. CK2 Molecular Targeting-Tumor Cell-Specific Delivery of RNAi in Various Models of Cancer. Pharmaceuticals (Basel) 10(2017).


    Nasry, W.H.S., Wang, H., Jones, K., Dirksen, W.P., Rosol, T.J., Rodriguez-Lecompte, J.C. & Martin, C.K. CD147 and Cyclooxygenase Expression in Feline Oral Squamous Cell Carcinoma. Veterinary sciences 5(2018).


    Piegols, H.J., Takada, M., Parys, M., Dexheimer, T. & Yuzbasiyan-Gurkan, V. Investigation of novel chemotherapeutics for feline oral squamous cell carcinoma. Oncotarget 9, 33098-33109 (2018).


    Borlle, L., Dergham, A., Wund, Z., Zumbo, B., Southard, T. & Hume, K.R. Salinomycin decreases feline sarcoma and carcinoma cell viability when combined with doxorubicin. BMC Vet Res 15, 36 (2019).


    Renzi, A., De Bonis, P., Morandi, L., Lenzi, J., Tinto, D., Rigillo, A., Bettini, G., Bellei, E. & Sabattini, S. Prevalence of p53 dysregulations in feline oral squamous cell carcinoma and non-neoplastic oral mucosa. PloS one 14, e0215621 (2019).


    Harris, K., Gelberg, H.B., Kiupel, M. & Helfand, S.C. Immunohistochemical Features of Epithelial-Mesenchymal Transition in Feline Oral Squamous Cell Carcinoma. Vet Pathol

This product has no review yet.
Controls and Related Product:

CAT.NO
G299
UNIT
10 Flasks
PRICE
$58.00

CAT.NO
G422
UNIT
25ml
PRICE
$310.00

CAT.NO
G255
UNIT
100ml
PRICE
$42.00

CAT.NO
TM024
UNIT
100ml
PRICE
$180.00

CAT.NO
TM001
UNIT
500 ml
PRICE
$131.00

CAT.NO
TM002
UNIT
500 ml
PRICE
$131.00

CAT.NO
TM003
UNIT
500 ml
PRICE
$131.00

CAT.NO
TM004
UNIT
500 ml
PRICE
$131.00
Other Cell Lines
SEARCH RESULT